The rabies vaccine market was valued at $1.31 billion in 2024 and is estimated to reach $2.04 billion by 2034, exhibiting a CAGR of 4.5% from 2025 to 2034.
Rabies remains a significant public health concern, particularly in regions where the disease is endemic. Rabies vaccine is primarily used for post-exposure prophylaxis (PEP) after potential exposure to rabid animals and for pre-exposure prophylaxis (PrEP) for individuals at higher risk, such as veterinarians, animal handlers, and travelers. The market for rabies vaccines is supported by the increasing recognition of rabies as a preventable disease and ongoing efforts to eliminate the disease globally. The rabies vaccine market is a major segment within the global healthcare industry, focused on the development, production, and distribution of vaccines designed to prevent rabies, a fatal viral disease transmitted through the saliva of infected animals.
Rise in awareness of rabies prevention and increase in demand for post-exposure vaccination drives the growth of the rabies vaccine industry. The World Health Organization (WHO) and other global health bodies have advocated for more widespread vaccination, leading to stronger vaccination campaigns and increased government funding, especially in endemic regions. Rapid urbanization, changes in wildlife & domestic animal populations, andan increase in international travel contribute to higher risks of rabies exposure, driving the demand for both PrEP and PEP vaccines. Furthermore, a rise in awareness of zoonotic diseases, diseases that are transmitted from animals to humans, has led to increased attention on rabies vaccination as a public health priority.
However, the high cost of rabies vaccines, particularly in low- and middle-income countries where resources for mass vaccination campaigns are limited, hinders the growth of the market. The vaccine’s complex administration schedule and the need for multiple doses in post-exposure scenarios also pose challenges. In addition, there are logistical barriers related to cold chain storage and transportation, especially in rural areas where access to healthcare facilities is limited. Moreover, despite efforts to improve vaccination rates, the global prevalence of stray dogs and wildlife that carry the rabies virus remains a significant challenge.
On the other hand, initiatives by the WHO and non-governmental organizations (NGOs) to reduce human rabies deaths through mass vaccination programs and dog population management are expected to drive market growth during the forecast period. In addition, the development of improved vaccines with longer shelf lives, simpler administration methods, and more cost-effective production processes could increase accessibility. The integration of advanced technologies, such as mobile health applications and digital monitoring systems for vaccine tracking, offers opportunities for enhancing vaccination coverage in underserved areas. Lastly, expanding public-private partnerships between governments, healthcare organizations, and vaccine manufacturers offer promising prospects for market growth and rabies control. In 2020, Merck partnered with the Global Alliance for Rabies Control (GARC) and the WHO to support initiatives for rabies elimination in high-risk areas through vaccination and educational campaigns.
Rabies remains a significant public health concern, particularly in regions where the disease is endemic. Rabies vaccine is primarily used for post-exposure prophylaxis (PEP) after potential exposure to rabid animals and for pre-exposure prophylaxis (PrEP) for individuals at higher risk, such as veterinarians, animal handlers, and travelers. The market for rabies vaccines is supported by the increasing recognition of rabies as a preventable disease and ongoing efforts to eliminate the disease globally. The rabies vaccine market is a major segment within the global healthcare industry, focused on the development, production, and distribution of vaccines designed to prevent rabies, a fatal viral disease transmitted through the saliva of infected animals.
Rise in awareness of rabies prevention and increase in demand for post-exposure vaccination drives the growth of the rabies vaccine industry. The World Health Organization (WHO) and other global health bodies have advocated for more widespread vaccination, leading to stronger vaccination campaigns and increased government funding, especially in endemic regions. Rapid urbanization, changes in wildlife & domestic animal populations, andan increase in international travel contribute to higher risks of rabies exposure, driving the demand for both PrEP and PEP vaccines. Furthermore, a rise in awareness of zoonotic diseases, diseases that are transmitted from animals to humans, has led to increased attention on rabies vaccination as a public health priority.
However, the high cost of rabies vaccines, particularly in low- and middle-income countries where resources for mass vaccination campaigns are limited, hinders the growth of the market. The vaccine’s complex administration schedule and the need for multiple doses in post-exposure scenarios also pose challenges. In addition, there are logistical barriers related to cold chain storage and transportation, especially in rural areas where access to healthcare facilities is limited. Moreover, despite efforts to improve vaccination rates, the global prevalence of stray dogs and wildlife that carry the rabies virus remains a significant challenge.
On the other hand, initiatives by the WHO and non-governmental organizations (NGOs) to reduce human rabies deaths through mass vaccination programs and dog population management are expected to drive market growth during the forecast period. In addition, the development of improved vaccines with longer shelf lives, simpler administration methods, and more cost-effective production processes could increase accessibility. The integration of advanced technologies, such as mobile health applications and digital monitoring systems for vaccine tracking, offers opportunities for enhancing vaccination coverage in underserved areas. Lastly, expanding public-private partnerships between governments, healthcare organizations, and vaccine manufacturers offer promising prospects for market growth and rabies control. In 2020, Merck partnered with the Global Alliance for Rabies Control (GARC) and the WHO to support initiatives for rabies elimination in high-risk areas through vaccination and educational campaigns.
Segment Review
The rabies vaccine market is segmented on the basis of product type, prophylaxis type, application, end user, and region. By product type, it is segregated into chick embryo cells rabies vaccine, vero cell rabies vaccine, human diploid cell vaccine, human rabies immune globulin (HRIG) and others. By prophylaxis type, it is classified into pre-exposure prophylaxis and post-exposure prophylaxis. By application, it is categorized into humans and animals. By end user, it is divided into hospitals, veterinary clinics, and others. By region, the market is studied across North America, Europe, Asia-Pacific, and LAMEA.Key Findings
- By product type, the chick embryo cells rabies vaccine segment held the major share of the market in 2024.
- By prophylaxis type, the post-exposure prophylaxis segment dominated the global rabies vaccine market in 2024.
- By application, the human segment dominated the rabies vaccine market in 2024.
- By end user, the hospitals segment dominated the rabies vaccine market in 2024.
- Region-wise, North America is anticipated to dominate the rabies vaccine market with the largest share during the forecast period.
Competition Analysis
The major players in the rabies vaccine market include Bharat Biotech International Limited, Zoetis, Sanofi, Boehringer Ingelheim International GmbH, Serum Institute of India Pvt. Ltd., Novartis AG, Cadila Pharmaceuticals, Merck & Co., Inc. Elanco Animal Health Incorporated., and Virbac SA. Key players operating in the market have adopted product approval, product launch, acquisition, and agreement as their key strategies to expand their rabies vaccine market share.Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the rabies vaccine market analysis from 2024 to 2034 to identify the prevailing rabies vaccine market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the rabies vaccine market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global rabies vaccine market trends, key players, market segments, application areas, and market growth strategies.
Additional benefits you will get with this purchase are:
- Quarterly update with the purchase of an enterprise license.
- 5 additional company profiles of your choice, pre- or post-purchase, as a free update.
- Free version update with the purchase of an Enterprise User License.
- 16 hours of analyst support.
- 15% free customization (Equivalent to 3 working days of work, applicable once).
- Free data pack (Excel) with the purchase of an Enterprise User License.
- Free updated report if the report is 6-12 months old or older.
- 24-hour priority response.
- Free industry updates and white papers.
Further possible customization (additional cost and timeline):
- Regulatory Guidelines
- Strategic Recommendations
- Additional company profiles with specific to client's interest
- Additional country or region analysis - market size and forecast
- Average Selling Price Analysis / Price Point Analysis
- Brands Share Analysis
- Criss-cross segment analysis - market size and forecast
- Expanded list for Company Profiles
- Historic market data
- Import Export Analysis/Data
- Key player details (including location, contact details, supplier/vendor network etc. in excel format)
- List of customers/consumers/raw material suppliers- value chain analysis
- Market share analysis of players at global/region/country level
- Product Consumption Analysis
- SWOT Analysis
- Volume Market Size and Forecast
Key Market Segments
By Product Type
- Chick Embryo Cells Rabies Vaccine
- Vero Cell Rabies Vaccine
- Human Diploid Cell Vaccine
- Human Rabies Immune Globulin (HRIG)
- Others
By Prophylaxis Type
- Pre-exposure prophylaxis
- Post-exposure prophylaxis
By Application
- Animal
- Human
By End User
- Hospitals
- Veterinary clinics
- Others
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia-Pacific
- LAMEA
- Brazil
- South Africa
- Saudi Arabia
- Rest of LAMEA
Key Market Players
- Merck & Co., Inc.
- Zoetis Inc.
- Bharat Biotech International Limited
- Novartis AG
- Virbac SA
- Boehringer Ingelheim International GmbH
- Sanofi
- Serum Institute of India Pvt. Ltd.
- Cadila Pharmaceuticals Ltd.
- Elanco Animal Health Incorporated
Table of Contents
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
CHAPTER 4: RABIES VACCINE MARKET, BY PRODUCT TYPE
CHAPTER 5: RABIES VACCINE MARKET, BY PROPHYLAXIS TYPE
CHAPTER 6: RABIES VACCINE MARKET, BY APPLICATION
CHAPTER 7: RABIES VACCINE MARKET, BY END USER
CHAPTER 8: RABIES VACCINE MARKET, BY REGION
CHAPTER 9: COMPETITIVE LANDSCAPE
CHAPTER 10: COMPANY PROFILES
LIST OF TABLES
LIST OF FIGURES
Companies Mentioned
- Merck & Co., Inc.
- Zoetis Inc.
- Bharat Biotech International Limited
- Novartis AG
- Virbac SA
- Boehringer Ingelheim International GmbH
- Sanofi
- Serum Institute of India Pvt. Ltd.
- Cadila Pharmaceuticals Ltd.
- Elanco Animal Health Incorporated
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
